The expert body now recognizes the test's ability to predict whether early-stage breast cancer patients will benefit from extended, adjuvant endocrine therapy.
Hologic said that Biotheranostics' PCR-based gene expression tests have been validated in large studies in areas of oncology with high growth potential.
The skin cancer diagnostics company said it delivered 7 percent more DecisionDx-Melanoma test results in Q3 2020 than in the previous year's third quarter.
Inflammatix said that if its test obtains Emergency Use Authorization next year, clinicians will be able to better gauge the severity of a COVID-19 patient's infection.
